XML 50 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Organization and Summary of Significant Accounting Policies - Narrative (Details)
€ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
segment
product
country
Jan. 01, 2021
USD ($)
Jan. 03, 2020
USD ($)
Dec. 31, 2021
EUR (€)
derivative_instrument
Organization And Summary Of Significant Policies [Line Items]        
Number of countries with FDA approval, excluding the U.S. | country 61      
Number of operating segments | segment 1      
Impairment charge on goodwill $ 0 $ 0 $ 0  
Percent discount for prompt payment 2.00%      
Discount expected to be earned 100.00%      
Medicare Part D funding mandate 70.00%      
Cost of goods sold is related to product 3.00%      
Advertising expense $ 31,800,000 $ 25,100,000 $ 17,900,000  
Foreign Exchange Forward        
Organization And Summary Of Significant Policies [Line Items]        
Number of forward contract outstanding | derivative_instrument       1
Forward contract outstanding, amount | €       € 9.8
Forward contract maturity (in months) 3 months      
Net gain on maturity of forward contracts $ 800,000      
Maximum        
Organization And Summary Of Significant Policies [Line Items]        
Estimated useful lives 15 years      
Resulting From Discovery Efforts        
Organization And Summary Of Significant Policies [Line Items]        
Number of products that entered in the commercial marketplace | product 4      
Products Derived From Other Compounds        
Organization And Summary Of Significant Policies [Line Items]        
Number of products that entered in the commercial marketplace | product 2